Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Pseudoephedrine hydrochloride

This article was originally published in The Tan Sheet

Executive Summary

Pseudoephedrine hydrochloride: FDA may now approve ANDAs for pseudoephedrine hydrochloride 120 mg extended-release capsules, the agency says in a notice published in the Oct. 29 Federal Register. FDA determined that the product, originally marketed by Burroughs Wellcome as Sudafed 12-Hour Capsules, was not withdrawn from the market for safety or effectiveness reasons, and therefore may be marketed by other companies after obtaining an approved ANDA. Burroughs Wellcome ceased marketing Sudafed 12-Hour Capsules and asked that FDA withdraw approval of the new drug application, which it did in September 1995. Drug manufacturer Eurand America requested permission to file an ANDA for the product in a June 1997 citizen petition. Eurand has developed a "taste-masked" pseudoephedrine that it markets to major drug companies ("The Tan Sheet" Feb. 5, 1996, In Brief). FDA will maintain the drug in the "Discontinued Drug Product List" section of the "Orange Book," the notice says...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087729

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel